Evolent Health (EVH) EBITDA (2015 - 2026)

Evolent Health has reported EBITDA for 12 years, with the latest figure at -$3.3 million in Q2 2026.

• On a quarterly basis, EBITDA fell 162.36% year-over-year to -$3.3 million in Q2 2026; TTM through Jun 2026 was -$402.3 million, a 4341.92% decrease from a year earlier, with the FY2025 full-year figure at -$383.8 million, down 3668.66% from the prior year.
• EBITDA was -$3.3 million for Q2 2026 at Evolent Health, up from -$4.3 million in the prior quarter.
• The five-year high for EBITDA was $20.7 million in Q3 2022, with the low at -$401.9 million in Q4 2025.
• Average EBITDA over 5 years is -$22.5 million, with a median of -$2.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA soared 4560.56% in 2022, then tumbled 3489.95% in 2025.
• Over 5 years, EBITDA stood at $7.0 million in 2022, then sank by 295.81% to -$13.8 million in 2023, then advanced by 18.57% to -$11.2 million in 2024, then sank by 3489.95% to -$401.9 million in 2025, then surged by 99.19% to -$3.3 million in 2026.
• The last three EBITDA figures came in at -$3.3 million (Q2 2026), -$4.3 million (Q1 2026), and -$401.9 million (Q4 2025), per Business Quant data.